Emerging Targets and Therapeutic Approaches banner

第7回年次会議「新興の標的と治療アプローチ」

技術の発展、理解の深まり、エンジニアリングアプローチの普及により、がん、自己免疫、炎症性疾患、その他のさまざまな適応症に対する新規標的の探索ペースが加速しています。「新興の標的と治療アプローチ」会議では、ターゲティングの改善による成功例と、残された課題に対する革新的なソリューションを紹介します。11月にリスボンで開催されるこの会議では、ファーストインクラスのバイオ医薬品を生み出すために研究中の驚くべき進歩や無数のソリューションを紹介します。

11月15日(水)

Registration Open and Morning Coffee07:30

INNOVATIVE APPROACHES TO THE CHALLENGES OF SOLID TUMOURS
固形がんの課題に対する革新的アプローチ

08:25

Chairperson's Opening Remarks

Kerry Chester, PhD, Professor, Molecular Medicine, University College London

08:30

Tumour Specific Immunogene Therapy to Deliver Protein Therapeutics to Solid Tumour Microenvironments

Samantha Bailey-Bucktrout, PhD, Senior Vice President, Akamis Bio

The tumour-specific immunogene platform (T-SIGn) has been designed to deliver protein therapeutics selectively to tumor microenvironments following systemic dosing and is moving into Phase 2 clinical testing. Novel antibody fragments have been expressed and validated, including single, bispecific, and biparatopic ScFv, and single and tandem VHH. The functionality of immune checkpoint inhibitors and immune inhibitors will be presented. Perspectives on the expression of combination therapeutics with fragment antibodies and other immune modulatory proteins within the solid tumour microenvironment will be discussed.

09:00

Local Secretion of Immune Active Proteins for Direct and Bystander Tumour Killing

Jonathan Fisher, PhD, Group Leader, University College London

Whilst striking success has been seen using CAR T cells to treat leukaemia and other cancers, the majority of solutions are autologous leading to high production costs and logistical challenges. Vg9Vd2-gdT cells are a versatile, non-alloreactive chassis for cellular immunotherapy, possessing potent antibody-dependent cellular cytotoxicity (ADCC) capacity, a tissue-tropic homing profile, and a range of innate tumour-sensing receptors minimizing the likelihood of tumour escape. OPS-gd is a cell therapy platform harnessing these properties, secreting tumour-targeting opsonins and armouring cytokines. OPS-gd cells show equivalent cytotoxicity but superior exhaustion phenotype to CAR-abT cells, recruitment of ADCC-competent bystanders, and in vivo efficacy against patient-derived osteosarcoma.

09:30 Talk Title to be Announced

Speaker to be Announced

Session Break to Transition into Plenary Keynote10:00

PLENARY KEYNOTE SESSION
基調講演(プレナリーセッション)

10:10

Introduction

Enkelejda Miho, PhD, Professor, Dean, University of Applied Sciences and Arts Northwestern Switzerland

10:15

Benchmarking the Impact of AI Biologics Discovery and Optimisation for Pharma

Rebecca Croasdale-Wood, PhD, Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology, AstraZeneca

The biologics landscape is rapidly changing with the number of AI-enabled biologics in pre-clinical and clinical stages estimated to be 50-60 (1). This change is driven by the increase in enterprise software solutions to capture and store data, augmented discovery workflows, improvements in machine learning technology, and advances in computing power. Augmented biologics discovery has the potential to revolutionize biologics discovery, yet information of how in silico technologies perform, versus traditional discovery platforms is scarce. At PEGS Europe, we will present current in silico biologics design and optimisation technologies, with a focus on our internal efforts to benchmark the impact of combining novel in silico technologies with our existing biologics discovery platforms.

Coffee Break in the Exhibit Hall with Poster Viewing11:00

INNOVATIVE APPROACHES TO THE CHALLENGES OF SOLID TUMOURS
固形がんの課題に対する革新的アプローチ

11:45 KEYNOTE PRESENTATION:

AI-Based Target and Antibody Discovery from Patient Tumour Profiles

Xiaole Shirley Liu, PhD, CEO, GV20 Therapeutics

Patient tumours contain anti-tumour antibodies but might not have sufficient abundance and correct Fc to cure the tumours. GV20 uses bioinformatics and AI to decode natural B-cell responses from large cohorts of patient tumours to uncover novel targets and antibodies simultaneously. It already brought a first-in-class antibody against a novel innate checkpoint to Ph1 clinical trial in the US.

12:15

The Influence of DM1, MMAE, and MMAF on Biodistribution and Preclinical Therapeutic Efficacy of Affibody-Based Drug Conjugates

Torbjorn Graslund, PhD, Professor, Department of Protein Science, KTH Royal Institute of Technology

Affibody molecules are small engineered alternative scaffold affinity proteins that can be site-specifically loaded with cytotoxic drugs to create homogenous conjugates with a desired drug-to-carrier ratio. The presentation will explore the targeting of HER2 and HER3 with affibody-based drug conjugates. It will also describe the impact on biodistribution and in vivo cytotoxic efficacy of drug conjugates loaded with auristatin and maytansine-derived payloads.

12:45 Antibody Discovery Using the Galaxy® Library Platform

Phil Jones, VP Discovery, RxBiologics Ltd

Galaxy® is our proprietary technology platform. Our ‘glass spleen’ approach incorporates the learnings of the in vivo selection process and allows us to access a far greater fraction of relevant antibody space. Based on the principle of ‘smart randomness’, it harnesses the incredible diversity found within human B cells. Furthermore, the design provides the potential to rapidly generate cheap to manufacture bispecifics without the need for any special technology or engineering.

13:00 Talk Title to be Announced

Speaker to be Announced

Session Break13:15

Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own13:20

Session Break14:20

14:30

Chairperson’s Remarks

Kerry Chester, PhD, Professor, Molecular Medicine, University College London

14:35

Structure-Guided Tuning of T Cell Receptors for HLA-A*03:01/A*11:01 Alloselectivity

Annelise Vuidepot, PhD, Senior Vice President and CTO, Immunocore

ADVANCES IN DISCOVERY AND ENGINEERING OF ANTIBODIES FOR NON-CANCER TARGETS
がん以外の標的に対する抗体の発見とエンジニアリング

15:05

Discovery of Broadly-Neutralizing Antibodies against Coronaviruses

Joshua Tan, PhD, Chief, Antibody Biology Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health

The potential for future coronavirus outbreaks and ongoing mutations in SARS-CoV-2 highlight the need to broadly target this group of pathogens. Here, we used an epitope-agnostic approach to identify two groups of monoclonal antibodies that target distinct regions of the spike protein and broadly neutralize diverse coronaviruses. Top neutralizers from both antibody classes neutralized all SARS-CoV-2 variants of concern tested including the Omicron subvariant XBB.1.5, inhibited fusion mediated by SARS-CoV-2 spike, and limited disease caused by SARS-CoV-2 in a Syrian hamster model. This two-step approach of isolating rare neutralizing mAbs against cryptic targets is highly relevant for pandemic prevention and the development of therapeutic tools against emerging pathogens.

Sponsored Presentation (Opportunity Available)15:35

Refreshment Break in the Exhibit Hall with Poster Viewing16:05

17:00

A Patient-First Approach to Discover First-in-Class Antibody Therapeutics

Jorge Dias, PhD, Principal Scientist, Alchemab Therapeutics Ltd.

Identifying genuinely novel targets that have immense therapeutic potential is an increasing challenge across central nervous system diseases. Alchemab addresses this challenge by truly disrupting the target discovery process - simply put, we let the patient select the best targets. We have discovered novel disease-relevant targets through our proprietary platform that searches for protective auto-antibodies in patients who are resistant to disease.

17:30

Advancing Snake Envenomation Treatment: Designing the Next Generation of Antivenoms

Sandra Ergueta-Carballo, PhD, Project Coordinator, University of Cambridge

Snake envenomation kills over 100,000 people annually and cripples three times as many. Current treatment relies on animal-derived serum, which, although life-saving presents many drawbacks, including lack of standardisation, a low proportion of neutralising antibodies, and serum sickness from injecting grams of animal protein. Therefore, it is crucial to modernise snakebite treatment. This presentation will show the ongoing efforts in developing the new generation of antivenoms and their associated challenges.

18:00

Advancing Brain Shuttle-Enabled Therapeutics for Efficient Delivery to CNS -Translation to Primates

Pawel Stocki, PhD, Vice President Research, Ossianix

Brain delivery across blood-brain barrier (BBB) is a major hurdle in the development of biological therapeutics for CNS disorders. We developed TXP1 brain shuttle based on anti-TfR1 antibody that can be fused to any therapeutic payload. In monkeys, TXP1 demonstrated ~35-fold improved brain penetration over the control, reaching up to 7.5% brain/plasma ratio. TXP1 showed to be safe and provided brain-specific delivery with no accumulation in other organs and had long-lasting brain PK, essential for efficacious CNS therapies.

18:30

Development of Autoregulating FVIII-Mimetic Bispecific Antibodies to Reduce Risk of Prothrombotic Events in Treatment of Haemophilia A

Vincent Muczynski, PhD, Director, NovalGen

Engineered proteins are powerful medicines, but may carry a risk of life-threatening toxicities. We have developed a broadly applicable approach of autoregulatable drugs by harnessing treatment-related biological signals to trigger inactivation of the drug at a set threshold through a negative feedback loop to prevent/attenuate high-grade adverse events. Using emicizumab, a marketed bispecific antibody for haemophilia A, we successfully demonstrated that autoregulation reduces frequency of thrombotic events.

Close of Emerging Targets and Therapeutic Approaches Conference19:00


* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
English



Premier Sponsors

Asimov Inc

Evitria

Immatics-Biotechnologies

Integral-Molecular_NEW

LONZA

Phenomex Logo